熱門資訊> 正文
Ensys赢得1400万美元联邦拨款用于铅止痛疗法
2024-08-27 20:43
- Nano-cap biotech Ensysce Biosciences (NASDAQ:ENSC) surged ~62% in the premarket trading on Tuesday after receiving a $14M grant from the U.S. government to support investigations into its lead pain therapy candidate PF614-MPAR.
- The funding issued by the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) will be available over approximately three years, allowing the company to complete a Phase 1b trial for PF614-MPAR. Ensysce (ENSC) said.
- Named PF614-MPAR-102, the trial builds on data from the company’s initial Phase 1 trial, PF614-MPAR-101, for the drug.
- Both PF614-MPAR-102 and PF614-MPAR-101 are expected to help the company introduce PF614-MPAR as the first opioid therapy with oral overdose protection, Ensysce (ENSC) said.
- The latest funding adds to $26M in federal grants allocated to the company for its Multi-Pill Abuse Resistance (MPAR) platform and its opioid use disorder (OUD) programs.
More on Ensysce Biosciences
- Seeking Alpha’s Quant Rating on Ensysce Biosciences
- Historical earnings data for Ensysce Biosciences
- Financial information for Ensysce Biosciences
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
